BG108518A - Crystalline forms vi and vii of atorvastatin calcium - Google Patents

Crystalline forms vi and vii of atorvastatin calcium

Info

Publication number: BG108518A
Authority: BG; Bulgaria
Prior art keywords: vii; crystalline forms; atorvastatin calcium; methods; relates
Prior art date: 2001-07-30

Application number

BG108518A

Other languages

Bulgarian (bg)

English (en)

Inventor

Satynarajana M. Reddy

Chakilam Nagaraju

Gudipati Shrinivasulu

Katakam Sinivas

Sagyam R. Reddy

Original Assignee

Dr.Reddy's Laboratories Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-30

Filing date

2004-01-09

Publication date

2004-08-31

2004-01-09 Application filed by Dr.Reddy's Laboratories Ltd. filed Critical Dr.Reddy's Laboratories Ltd.

2004-08-31 Publication of BG108518A publication Critical patent/BG108518A/xx

Links

OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title abstract 2
229960001770 atorvastatin calcium Drugs 0.000 title abstract 2
238000000034 method Methods 0.000 abstract 2
XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
159000000007 calcium salts Chemical class 0.000 abstract 1
238000002955 isolation Methods 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Obesity (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pyrrole Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

BG108518A 2001-07-30 2004-01-09 Crystalline forms vi and vii of atorvastatin calcium BG108518A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN620MA2001		2001-07-30
PCT/US2002/000431 WO2003011826A1 (fr)	2001-07-30	2002-01-07	Formes cristallines vi et vii de calcium d'atorvastatine

Publications (1)

Publication Number	Publication Date
BG108518A true BG108518A (en)	2004-08-31

Family

ID=35160889

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108518A BG108518A (en)	2001-07-30	2004-01-09	Crystalline forms vi and vii of atorvastatin calcium

Country Status (19)

Country	Link
EP (2)	EP1414796A1 (fr)
JP (1)	JP2005500351A (fr)
KR (1)	KR20040019043A (fr)
CN (1)	CN100471836C (fr)
AU (1)	AU2002255479B2 (fr)
BG (1)	BG108518A (fr)
BR (1)	BR0211488A (fr)
CA (1)	CA2454500C (fr)
CZ (1)	CZ2004126A3 (fr)
EE (1)	EE200400048A (fr)
HR (1)	HRP20040077A2 (fr)
IL (2)	IL159626A0 (fr)
MX (1)	MXPA04000889A (fr)
NO (1)	NO20040390L (fr)
NZ (1)	NZ530785A (fr)
PL (1)	PL368647A1 (fr)
RU (1)	RU2304139C2 (fr)
WO (1)	WO2003011826A1 (fr)
ZA (1)	ZA200400573B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7411075B1 (en)	2000-11-16	2008-08-12	Teva Pharmaceutical Industries Ltd.	Polymorphic form of atorvastatin calcium
KR100704213B1 (ko) *	2000-11-03	2007-04-10	테바 파마슈티컬 인더스트리즈 리미티드	아토르바스타틴 헤미-칼슘 ｖｉｉ형
US7501450B2 (en)	2000-11-30	2009-03-10	Teva Pharaceutical Industries Ltd.	Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en)	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (fr) *	2000-12-27	2002-07-04	Teva Pharmaceutical Industries Ltd.	Formes cristallines d'atorvastatine
CA2475864A1 (fr) *	2002-02-15	2003-08-28	Teva Pharmaceutical Industries Ltd.	Nouvelles formes cristallines d'hemi-calcium d'atorvastatine
HRP20040767A2 (en)	2002-02-19	2004-12-31	Teva Pharma	Desolvating solvates of atorvastatin hemi-calcium
WO2004050618A2 (fr) *	2002-11-28	2004-06-17	Teva Pharmaceutical Industries Ltd.	Forme cristalline
EP1424324A1 (fr) *	2002-11-28	2004-06-02	Teva Pharmaceutical Industries Limited	Forme cristalline F de calcium d'atorvastatine
US7655692B2 (en)	2003-06-12	2010-02-02	Pfizer Inc.	Process for forming amorphous atorvastatin
US20050271717A1 (en)	2003-06-12	2005-12-08	Alfred Berchielli	Pharmaceutical compositions of atorvastatin
WO2005090301A1 (fr) *	2004-03-17	2005-09-29	Ranbaxy Laboratories Limited	Forme cristalline d'hemi-calcium d'atorvastatine
WO2005092852A1 (fr)	2004-03-17	2005-10-06	Ranbaxy Laboratories Limited	Procede de production d'atorvastatine calcique sous forme amorphe
CA2573969C (fr) *	2004-07-16	2014-02-04	Lek Pharmaceuticals D.D.	Produits de degradation oxydante du calcium d'atorvastatine
JP2008506764A (ja)	2004-07-20	2008-03-06	ワーナー−ランバートカンパニーリミテッドライアビリティーカンパニー	［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
WO2006037125A1 (fr)	2004-09-28	2006-04-06	Teva Pharmaceutical Industries Ltd.	Procede de preparation de formes d'atorvastatine calcique sensiblement exemptes d'impuretes
WO2006046109A1 (fr)	2004-10-28	2006-05-04	Warner-Lambert Company Llc	Procede de formation d'atorvastatine amorphe
WO2006048894A1 (fr) *	2004-11-05	2006-05-11	Morepen Laboratories Limited	Nouvelles formes cristallines de calcium d'atorvastatine et procedes de fabrication
US8080672B2 (en)	2005-12-13	2011-12-20	Teva Pharmaceutical Industries Ltd.	Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
WO2009007856A2 (fr) *	2007-07-11	2009-01-15	Actavis Group Ptc Ehf	Nouveau polymorphe d'atorvastatine calcium et son utilisation pour la préparation d'atorvastatine calcium amorphe
KR20120011249A (ko)	2010-07-28	2012-02-07	주식회사 경보제약	아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
CN104983702A (zh) *	2015-07-23	2015-10-21	青岛蓝盛洋医药生物科技有限责任公司	一种治疗高胆固醇血症的药物阿托伐他汀钙组合物片剂
CN108157405B (zh) *	2018-02-06	2020-10-02	上海应用技术大学	一种灭蟑螂饵剂及其制备方法和应用
WO2025147589A1 (fr)	2024-01-05	2025-07-10	Osanni Bio, Inc.	Implants, compositions et méthodes de traitement de maladies et de troubles de la rétine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5245047A (en)	1988-02-22	1993-09-14	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en)	1988-02-22	1993-06-01	Warner-Lambert Co.	Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5124482A (en)	1988-02-22	1992-06-23	Warner-Lambert Company	Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en)	1989-02-01	1992-03-17	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en)	1988-02-22	1991-03-26	Warner-Lambert Company	Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5149837A (en)	1988-02-22	1992-09-22	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5248793A (en)	1990-10-17	1993-09-28	Warner-Lambert Company	Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en)	1990-10-17	1992-04-07	Warner-Lambert Company	Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en)	1991-10-11	1992-10-13	Warner-Lambert Company	Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en)	1993-03-03	1994-03-29	Warner-Lambert Company	Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
IL109570A0 (en) *	1993-05-17	1994-08-26	Fujisawa Pharmaceutical Co	Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
HRP960313B1 (en) *	1995-07-17	2002-08-31	Warner Lambert Co	Form iii crystalline (r- (r, r)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
GEP20002029B (en)	1995-07-17	2000-04-10	Warner Lambert Company Us	(54) Crystalline [R-(R,R,]–2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl–4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin)
US6087511A (en)	1996-07-16	2000-07-11	Warner-Lambert Company	Process for the production of amorphous [R-(R,R)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5929156A (en)	1997-05-02	1999-07-27	J.M. Huber Corporation	Silica product for use in elastomers
HU226640B1 (en)	1999-10-18	2009-05-28	Egis Gyogyszergyar Nyilvanosan	Process for producing amorphous atorvastatin calcium salt
ES2234699T3 (es)	1999-11-17	2005-07-01	Teva Pharmaceutical Industries Ltd.	Forma polimorfica de atorvastatina calcio.
KR100704213B1 (ko) *	2000-11-03	2007-04-10	테바 파마슈티컬 인더스트리즈 리미티드	아토르바스타틴 헤미-칼슘 ｖｉｉ형
PL362981A1 (en) *	2000-11-16	2004-11-02	Teva Pharmaceutical Industries Ltd.	Hydrolysis of [r(r,r)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
IL156055A0 (en) *	2000-11-30	2003-12-23	Teva Pharma	Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CA2622477A1 (fr) *	2000-12-27	2002-07-04	Teva Pharmaceutical Industries Ltd.	Formes cristallines d'atorvastatine
WO2002057229A1 (fr) *	2001-01-19	2002-07-25	Biocon India Limited	FORME V CRISTALLINE DE SEL HEMICALCIQUE D'ACIDE [R-(R,R)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIQUE (ATORVASTATINE)

2002
- 2002-01-07 AU AU2002255479A patent/AU2002255479B2/en not_active Ceased
- 2002-01-07 RU RU2004103470/04A patent/RU2304139C2/ru not_active IP Right Cessation
- 2002-01-07 NZ NZ530785A patent/NZ530785A/en not_active IP Right Cessation
- 2002-01-07 CN CNB028150708A patent/CN100471836C/zh not_active Expired - Fee Related
- 2002-01-07 IL IL15962602A patent/IL159626A0/xx unknown
- 2002-01-07 CZ CZ2004126A patent/CZ2004126A3/cs unknown
- 2002-01-07 KR KR10-2004-7000093A patent/KR20040019043A/ko not_active Ceased
- 2002-01-07 PL PL02368647A patent/PL368647A1/xx unknown
- 2002-01-07 EP EP02724877A patent/EP1414796A1/fr not_active Withdrawn
- 2002-01-07 WO PCT/US2002/000431 patent/WO2003011826A1/fr not_active Ceased
- 2002-01-07 EE EEP200400048A patent/EE200400048A/xx unknown
- 2002-01-07 JP JP2003517018A patent/JP2005500351A/ja active Pending
- 2002-01-07 EP EP10010845A patent/EP2292600A1/fr not_active Withdrawn
- 2002-01-07 HR HR20040077A patent/HRP20040077A2/xx not_active Application Discontinuation
- 2002-01-07 CA CA002454500A patent/CA2454500C/fr not_active Expired - Fee Related
- 2002-01-07 MX MXPA04000889A patent/MXPA04000889A/es active IP Right Grant
- 2002-01-07 BR BR0211488-7A patent/BR0211488A/pt not_active Application Discontinuation
2003
- 2003-12-29 IL IL159626A patent/IL159626A/en not_active IP Right Cessation
2004
- 2004-01-09 BG BG108518A patent/BG108518A/xx unknown
- 2004-01-26 ZA ZA200400573A patent/ZA200400573B/en unknown
- 2004-01-29 NO NO20040390A patent/NO20040390L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2454500C (fr)	2009-11-10
ZA200400573B (en)	2005-05-11
EE200400048A (et)	2004-04-15
CZ2004126A3 (cs)	2004-12-15
IL159626A (en)	2013-04-30
HRP20040077A2 (en)	2004-06-30
AU2002255479B2 (en)	2008-09-11
RU2304139C2 (ru)	2007-08-10
EP2292600A1 (fr)	2011-03-09
MXPA04000889A (es)	2004-06-03
KR20040019043A (ko)	2004-03-04
BR0211488A (pt)	2004-08-17
RU2004103470A (ru)	2005-06-20
JP2005500351A (ja)	2005-01-06
CA2454500A1 (fr)	2003-02-13
NZ530785A (en)	2005-10-28
CN100471836C (zh)	2009-03-25
PL368647A1 (en)	2005-04-04
CN1537098A (zh)	2004-10-13
NO20040390L (no)	2004-01-29
IL159626A0 (en)	2004-06-01
EP1414796A1 (fr)	2004-05-06
WO2003011826A1 (fr)	2003-02-13

Publication	Publication Date	Title
BG108518A (en)	2004-08-31	Crystalline forms vi and vii of atorvastatin calcium
HRP20031039A2 (en)	2005-10-31	Crystalline forms of 'r-(r,r)^-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl^-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
YU36802A (sh)	2005-09-19	Postupak za dobijanje amorfnog atorvastatina
EP1783113A3 (fr)	2007-05-30	Forme cristalline VII d'hémi-calcium d'atorvastatine
BG102186A (en)	1998-10-30	Crystalline form iii of hemicalcium salts of [r-(r, r)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin)
HRP960339B1 (en)	2002-06-30	Crystalline /r- (r, r)/-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-/(phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid hemi calcium salt
DK0839132T5 (da)	2006-03-20	Fremgangsmåde til fremstilling af amorft [R-(R,R)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1)
YU56803A (sh)	2006-05-25	Pripremanje nekristalinskog atorvastatin-kalcijuma
HUP0402590A3 (en)	2010-06-28	Method of manufacturing an amorphous form of the hemi-calcium salt of (3r,5r)7-3-phenyl-4-phenylcarbomoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl!-3, 5-dihydroxyheptanoic acid (atorvastatin)
PL370061A1 (en)	2005-05-16	Crystalline (r-(r,r))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-heptanoic acid calcium salt (2:1)
CA2508871A1 (fr)	2004-06-17	Forme cristalline f de sel d'hemi-calcium d'astorvastatine
IL173651A0 (en)	2006-07-05	Crystalline forms of [r-(r,r)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
PL349307A1 (en)	2003-03-10	Novel crystalline form of semi-calcium [r-(r ,r)]-2-(4-fluorophenyl)-beta, dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl)-1h-pyrrole-1-heptanic salt (athorovastatin), method of obtaining same, pharmacological composition containing such salt and medical application thereof
CA2522899A1 (fr)	2003-01-16	Formes cristallines de sel hemicalcique d'acide [r-(r,r)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoique (2:1)(atorvastatine)
ZA200303974B (en)	2004-08-23	Hydrolysis of [R(R,R)]-2-(4-Fluorophenyl)-b,D-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic acid esters with calcium hydroxide.
IS7019A (is)	2003-11-10	Kristallaform af 'R-(R,R)!-2-(4-flúorfenýl)-beta, delta-díhýdroxý-5-(1-metýletýl)-3-fenýl-4-'fenýlamínó)karbónýl!-1H-pýrról-1-heptansýru kalsíum salt (2:1) (atorvastatín)
AU2001234058A1 (en)	2002-07-30	Form v crystalline (r-(r,r))-2-(4-fluorophenyl)-ss,$g(d)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1- heptanoic acid hemi calcium salt. (atorvastatin)
HK1056556A (en)	2004-02-20	HYDROLYSIS OF [R(R,R)]-2-(4-FLUOROPHENYL)-β, δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE